STERIS plc (STE)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $25.67B
Last updated: Nov 17, 2026 at 11:06 AM ET
STERIS plc (STE) Earnings: Report Dates and Results
STERIS (STE) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, STERIS reported EPS of $2.94, above the $2.67 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
STE has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 10.7% above the $2.53 reported for the quarter ended Dec 31, 2025.
STE Earnings Call
The latest STE earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, STE beat 32, missed 4 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $1.59B, up 8.9% from $1.46B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.94 | $2.67 | $2.66 - $2.70 | +10.11% | Beat | +19.0% | 6 | 0 up, 0 down | Nov 4, 2026 | $1.59B |
| Jun 30, 2026 | $2.59 | $2.54 | $2.44 - $2.58 | +1.97% | Beat | +10.7% | 8 | 2 up, 2 down | Aug 5, 2026 | $1.49B |
| Mar 31, 2026 | $2.83 | $2.85 | $2.81 - $2.90 | -0.70% | Miss | +3.3% | 7 | 1 up, 6 down | May 11, 2026 | $1.59B |
| Dec 31, 2025 | $2.53 | $2.53 | $2.47 - $2.61 | 0.00% | In line | +9.1% | 8 | 2 up, 3 down | Feb 4, 2026 | $1.50B |
| Sep 30, 2025 | $2.47 | $2.38 | $2.31 - $2.42 | +3.78% | Beat | +15.4% | 8 | 0 up, 1 down | Nov 5, 2025 | $1.46B |
| Jun 30, 2025 | $2.34 | $2.26 | $2.18 - $2.33 | +3.54% | Beat | +15.3% | 8 | N/A | Aug 6, 2025 | $1.39B |
| Mar 31, 2025 | $2.74 | $2.60 | $2.57 - $2.61 | +5.38% | Beat | +6.2% | 7 | 0 up, 1 down | May 14, 2025 | $1.48B |
| Dec 31, 2024 | $2.32 | $2.32 | $2.29 - $2.35 | 0.00% | In line | +4.5% | 7 | 2 up, 5 down | Feb 5, 2025 | $1.37B |
| Sep 30, 2024 | $2.14 | $2.13 | $2.10 - $2.16 | +0.47% | Beat | +3.4% | 7 | 0 up, 1 down | Nov 6, 2024 | $1.33B |
| Jun 30, 2024 | $2.03 | $1.98 | $1.92 - $2.02 | +2.53% | Beat | +1.5% | 7 | 0 up, 1 down | Aug 6, 2024 | $1.28B |
| Mar 31, 2024 | $2.58 | $2.41 | $2.20 - $2.42 | +7.05% | Beat | +12.2% | 7 | 0 up, 1 down | May 8, 2024 | $1.42B |
| Dec 31, 2023 | $2.22 | $2.17 | $2.15 - $2.22 | +2.30% | Beat | +9.9% | 7 | 0 up, 0 down | Feb 7, 2024 | $1.30B |
| Sep 30, 2023 | $2.07 | $2.00 | $1.90 - $2.07 | +3.50% | Beat | +4.0% | 6 | 0 up, 0 down | Nov 7, 2023 | $1.24B |
| Jun 30, 2023 | $2.00 | $1.86 | $1.80 - $1.91 | +7.53% | Beat | +5.3% | 6 | 0 up, 1 down | Aug 1, 2023 | $1.18B |
| Mar 31, 2023 | $2.30 | $2.15 | $2.13 - $2.16 | +6.98% | Beat | +12.7% | 6 | 1 up, 0 down | May 10, 2023 | $963.26M |
| Dec 31, 2022 | $2.02 | $2.19 | $2.17 - $2.26 | -7.76% | Miss | -4.7% | 6 | 0 up, 0 down | Feb 8, 2023 | $1.22B |
| Sep 30, 2022 | $1.99 | $1.98 | $1.93 - $2.04 | +0.51% | Beat | 0.0% | 6 | 0 up, 0 down | Nov 9, 2022 | $1.20B |
| Jun 30, 2022 | $1.90 | $1.90 | $1.86 - $2.00 | 0.00% | In line | +8.0% | 6 | 1 up, 0 down | Aug 2, 2022 | $1.16B |
| Mar 31, 2022 | $2.04 | $2.02 | $2.00 - $2.04 | +0.99% | Beat | +25.2% | 5 | 0 up, 0 down | May 11, 2022 | $849.02M |
| Dec 31, 2021 | $2.12 | $1.96 | $1.95 - $2.00 | +8.16% | Beat | +22.5% | 5 | 0 up, 1 down | Feb 8, 2022 | $1.21B |
| Sep 30, 2021 | $1.99 | $1.82 | $1.71 - $1.86 | +9.34% | Beat | +34.5% | 5 | 0 up, 0 down | Nov 2, 2021 | $1.20B |
| Jun 30, 2021 | $1.76 | $1.49 | $1.43 - $1.52 | +18.12% | Beat | +34.4% | 5 | N/A | Aug 9, 2021 | $968.42M |
| Mar 31, 2021 | $1.63 | $1.80 | $1.75 - $1.81 | -9.44% | Miss | -0.6% | 6 | N/A | May 18, 2021 | $873.53M |
| Dec 31, 2020 | $1.73 | $1.54 | $1.41 - $1.58 | +12.34% | Beat | +19.3% | 6 | N/A | Feb 2, 2021 | $808.92M |
| Sep 30, 2020 | $1.48 | $1.27 | $1.21 - $1.34 | +16.54% | Beat | +12.1% | 6 | N/A | Nov 2, 2020 | $756.13M |
| Jun 30, 2020 | $1.31 | $0.98 | $0.85 - $1.03 | +33.67% | Beat | +6.5% | 5 | N/A | Aug 3, 2020 | $668.93M |
| Mar 31, 2020 | $1.64 | $1.58 | $1.51 - $1.62 | +3.80% | Beat | +7.2% | 4 | N/A | May 13, 2020 | $822.99M |
| Dec 31, 2019 | $1.45 | $1.42 | $1.39 - $1.47 | +2.11% | Beat | +15.1% | 5 | N/A | Feb 10, 2020 | $774.26M |
| Sep 30, 2019 | $1.32 | $1.25 | $1.23 - $1.30 | +5.60% | Beat | +20.0% | 6 | N/A | Nov 4, 2019 | $736.84M |
| Jun 30, 2019 | $1.23 | $1.11 | $1.08 - $1.12 | +10.81% | Beat | +23.0% | 7 | N/A | Aug 5, 2019 | $696.80M |
| Mar 31, 2019 | $1.53 | $1.43 | $1.40 - $1.45 | +6.99% | Beat | +23.4% | 7 | N/A | May 13, 2019 | $768.21M |
| Dec 31, 2018 | $1.26 | $1.25 | $1.20 - $1.30 | +0.80% | Beat | +12.5% | 8 | N/A | Feb 11, 2019 | $696.24M |
| Sep 30, 2018 | $1.10 | $1.09 | N/A | +0.92% | Beat | +17.0% | N/A | N/A | Nov 6, 2018 | $678.96M |
| Jun 30, 2018 | $1.00 | $0.99 | $0.95 - $1.03 | +1.01% | Beat | +17.6% | 8 | N/A | Aug 8, 2018 | $638.76M |
| Mar 31, 2018 | $1.24 | $1.22 | $1.20 - $1.23 | +1.64% | Beat | +11.7% | 8 | N/A | May 9, 2018 | $715.97M |
| Dec 31, 2017 | $1.12 | $1.07 | $1.04 - $1.11 | +4.67% | Beat | +14.3% | 8 | N/A | Feb 7, 2018 | $661.90M |
| Sep 30, 2017 | $0.94 | $0.94 | $0.92 - $1.00 | 0.00% | In line | +5.6% | 8 | N/A | Nov 1, 2017 | $634.16M |
| Jun 30, 2017 | $0.85 | $0.80 | $0.78 - $0.82 | +6.25% | Beat | +7.6% | 8 | N/A | Aug 8, 2017 | $607.96M |
| Mar 31, 2017 | $1.11 | $1.06 | N/A | +4.72% | Beat | +23.3% | N/A | N/A | May 9, 2017 | $681.19M |
| Dec 31, 2016 | $0.98 | $1.03 | N/A | -4.85% | Miss | 0.0% | N/A | N/A | Feb 7, 2017 | $646.77M |
Annual EPS
EPS for the fiscal year ended Mar 31, 2026 was $10.17, up 10.2% from the year before. It was $3.77 for the year ended Mar 31, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Mar 31, 2026 | $10.17 | +10.2% |
| Mar 31, 2025 | $9.23 | +4.1% |
| Mar 31, 2024 | $8.87 | +8.0% |
| Mar 31, 2023 | $8.21 | +3.8% |
| Mar 31, 2022 | $7.91 | +28.6% |
| Mar 31, 2021 | $6.15 | +9.0% |
| Mar 31, 2020 | $5.64 | +15.3% |
| Mar 31, 2019 | $4.89 | +17.8% |
| Mar 31, 2018 | $4.15 | +10.1% |
| Mar 31, 2017 | $3.77 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,300 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,325 | 10 | |
| 2026Q2 | Jun 30, 2026 | 3,055 | 9 | |
| 2026Q1 | Mar 31, 2026 | 3,806 | 12 | |
| 2025Q4 | Dec 31, 2025 | 3,800 | 11 | |
| 2025Q3 | Sep 30, 2025 | 4,616 | 11 | |
| 2025Q2 | Jun 30, 2025 | 3,414 | 10 | |
| 2025Q1 | Mar 31, 2025 | 3,440 | 10 | |
| 2024Q4 | Dec 31, 2024 | 3,351 | 9 |
2026Q3 Earnings Call
Opening remarks
Julie Winter Vice President, Investor Relations Thank you, Teck, and good morning, everyone. Speaking on today's call will be Karen Burton, our Senior Vice President and Chief Financial Officer, and Daniel A. Carestio, our President and Chief Executive Officer.
Karen Burton Senior Vice President and Chief Financial Officer I do have a few words of caution before we open for comments. This webcast contains time-sensitive information that is only as of today. Any redistribution, retransmission, or rebroadcast of this call without the express written consent of STERIS is strictly prohibited. Some of the statements made during this review may be considered forward-looking statements. Many important factors could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, those risk factors described in STERIS' securities filings. The company does not undertake to update or revise any forward-looking statements as a result of new information or future events or developments. STERIS' SEC filings are available through the company and on our website. In addition, on today's call, non-GAAP financial measures, including adjusted earnings per diluted share, adjusted operating income, constant currency organic revenue growth, and free cash flow will be used. Additional information regarding these measures, including definitions, is available in our press release as well as reconciliations between GAAP and non-GAAP financial measures. Non-GAAP financial measures are presented during this call with the intent of providing greater transparency to supplemental financial information used by management and the board of directors in their financial analysis and operational decision-making. With those cautions, I will hand the call over to Dan for his remarks. Thank you, and good morning, everyone. It is my pleasure to be with you this morning to review the highlights of our third-quarter performance from continuing operations. For the third quarter, total as-reported revenue grew 9%. Constant currency organic revenue grew 8% in the quarter, driven by volume as well as 200 basis points of price. Gross margin for the quarter declined 70 basis points compared with the prior year to 43.9%. Positive price and productivity, primarily driven by volume, were more than offset by increased tariffs and inflation. EBIT margin decreased 40 basis points to 22.9% of revenue compared with last year, mainly driven by the decline in gross margin, which was somewhat mitigated by operating expense discipline. The adjusted effective tax rate in the quarter was 24.2%, a small decline from 24.5% in the third quarter of last year. The year-over-year decrease was driven primarily by changes in geographic mix. Adjusted net income from continuing operations in the quarter was $249.4 million. Earnings per diluted share from continuing operations were $2.53, a 9% increase over the prior year. Capital expenditures for the first nine months of fiscal 2026 totaled $278.8 million, and depreciation and amortization totaled $363.1 million.
Frequently Asked Questions About STE
When is STERIS's next earnings date?
STERIS's next earnings report is expected for Feb 2, 2027.
Did STE beat earnings estimates last quarter?
Yes. STERIS reported EPS of $2.94 for the quarter ended Sep 30, 2026, above the $2.67 estimate, a 10.11% surprise.
What EPS do analysts expect from STE next quarter?
The consensus EPS estimate for STERIS for the quarter ending Dec 31, 2026 is $2.80 from 7 analysts, with estimates from $2.78 to $2.83.
How often does STE beat earnings estimates?
STERIS beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.01%.
STE pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts